Starling Oncology, Inc.
STLNHealthcareNASDAQMedical Care Facilities · Last scanned Oct 26, 2026
Scan Results
Daily timeframeStarling Oncology, Inc., an oncology company, provides various oncology services in the United States. The company carries a $683.9M market cap, placing it firmly in the small-cap category. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.
Market Cap
$683.9M
Beta
0.42
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.29
EPS (Fwd)
—
ROE
—
ROA
-9.7%
Cash
$41.1M
Total Debt
$104.8M
Free CF
$8.6M
52W Change
45.6%
Annual Financials
Cash vs Debt
Where STLN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, STLN finished 26.92% above its 150-day moving average ($5.09) and 41.36% above its 200-day moving average ($4.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STLN overbought or oversold?
At the October 20, 2026 close, STLN's RSI(14) was 49.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Starling Oncology, Inc. carries $104.8M in total debt against $41.1M in cash reserves — debt is roughly 2.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $8.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Revenue has grown from $252.5M (2022) to $502.7M (2025), reflecting a 99% increase over the period.
The relatively low beta of 0.42 suggests STLN is a less volatile holding compared to the broader index. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Starling Oncology, Inc.'s trajectory.